NCT03379311 - A Study of AK002 in Patients With Atopic Keratoconjunctivitis, Vernal Keratoconjunctivitis, and Perennial Allergic Conjunctivitis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 26, 2018

Primary Completion Date

August 8, 2019

Study Completion Date

August 8, 2019

Conditions

Atopic KeratoconjunctivitisVernal KeratoconjunctivitisPerennial Allergic Conjunctivitis

Interventions

DRUG

AK002

AK002 is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8, a member of the CD33-related family of sialic acid-binding, immunoglobulin-like lectins (Siglecs).

Trial Locations (8)

15213

UPMC Eye Center, Pittsburgh

21201

University of Maryland, Department of Ophthalmology and Visual Sciences, Baltimore

32132

Riverside Clinical Research, Edgewater

63131

Ophthalmology Associates, St Louis

64111

Tauber Eye Center, Kansas City

94303

Byers Eye Institute at Stanford University, Palo Alto

02451

Ocular Immunology and Uveitis Foundation, Waltham

07650

Metropolitan Eye Research and Surgery Institute, Palisades Park